Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

(cid:1) Insuf fi cient control of motor complications (or drug-resistant tremor in the case of DBS) are in- dications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged > 70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

[1]  Joseph H Friedman,et al.  Nonmotor Symptoms in Parkinson's Disease , 2017, Seminars in Neurology.

[2]  W. Poewe,et al.  Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. , 2015, Parkinsonism & related disorders.

[3]  R. Hawes,et al.  Gastrointestinal Safety of the Levodopa-Carbidopa Intestinal Gel Delivery System in Treating Advanced Parkinson’s Patients (P7.085) , 2014 .

[4]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[5]  I. Forgacs,et al.  Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD) , 2014, Health and Quality of Life Outcomes.

[6]  G. Deuschl,et al.  Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits , 2013, The Lancet Neurology.

[7]  K. Chaudhuri,et al.  Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease , 2013 .

[8]  P. Deyn,et al.  Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care , 2013, Journal of Neural Transmission.

[9]  P. Worth.  When the going gets tough: how to select patients with Parkinson's disease for advanced therapies , 2013, Practical Neurology.

[10]  Alberto J Espay,et al.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. , 2013, Parkinsonism & related disorders.

[11]  R. Albin,et al.  Dopaminergic treatment and nonmotor features of Parkinson disease , 2013, Neurology.

[12]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[13]  L. Bour,et al.  Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial , 2013, The Lancet Neurology.

[14]  G. Deuschl,et al.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.

[15]  A. Berardelli,et al.  Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease , 2013, European journal of neurology.

[16]  Gabriele Schackert,et al.  Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[17]  I. Forgacs,et al.  Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects , 2012, Clinical neuropharmacology.

[18]  Eric Seigneuret,et al.  Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. , 2012, Brain : a journal of neurology.

[19]  J. Lökk.  Lack of information and access to advanced treatment for Parkinson’s disease patients , 2011, Journal of multidisciplinary healthcare.

[20]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[21]  Angelo Antonini,et al.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation , 2011, Journal of Neurology.

[22]  F. Horak,et al.  A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD , 2010, Neurology.

[23]  Jens Volkmann,et al.  Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease , 2010, Nature Reviews Neurology.

[24]  Grant D. Huang,et al.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.

[25]  Keith Wheatley,et al.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial , 2010, The Lancet Neurology.

[26]  I. Forgacs,et al.  Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.

[27]  D. Bowers,et al.  Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE Trial , 2009, Annals of neurology.

[28]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[29]  Yong Hoon Lim,et al.  Chronic subthalamic deep brain stimulation improves pain in Parkinson disease , 2008, Journal of Neurology.

[30]  W. Oertel,et al.  Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.

[31]  M. Lanotte,et al.  Motor and Nonmotor Symptom Follow-Up in Parkinsonian Patients after Deep Brain Stimulation of the Subthalamic Nucleus , 2007, European Neurology.

[32]  A. Antonini.  Continuous dopaminergic stimulation--from theory to clinical practice. , 2007, Parkinsonism & related disorders.

[33]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[34]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[35]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[36]  Andrew Evans,et al.  Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.

[37]  E. Tolosa,et al.  Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[38]  J. Villemure,et al.  Absence of cholinergic deficits in “pure” vascular dementia , 2005, Neurology.

[39]  S. Fox,et al.  A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease , 2004, Journal of Neurology.

[40]  P. Derambure,et al.  Effects of bilateral subthalamic stimulation on sleep in Parkinson’s disease , 2004, Journal of Neurology.

[41]  A. Antonini,et al.  Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease , 2003, Neurological Sciences.

[42]  Andrew J Lees,et al.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.

[43]  J. Burgunder,et al.  Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[44]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[45]  E. Tolosa,et al.  Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation , 2002, Journal of neurology, neurosurgery, and psychiatry.

[46]  P. Odin,et al.  Apomorphine in the Treatment of Parkinson's Disease , 2001, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[47]  L. Vacca,et al.  Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results , 2001, Neurological Sciences.

[48]  Y. Agid,et al.  Improvement of sleep architecture in PD with subthalamic nucleus stimulation , 2000, Neurology.

[49]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[50]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[51]  K. Chaudhuri,et al.  SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASE , 1988, The Lancet.

[52]  A. Lees,et al.  SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS , 1988, The Lancet.

[53]  L. Miller,et al.  Patient Profile , 1981, RDH.

[54]  A. Antonini,et al.  Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. , 2014, Parkinsonism & related disorders.

[55]  J. Péron,et al.  Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. , 2012, Parkinsonism & related disorders.

[56]  E. Wolters,et al.  Selecting patients for continuous dopaminergic stimulation therapy , 2011 .

[57]  K. Chaudhuri,et al.  Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.

[58]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[59]  D. Nyholm,et al.  The Concept of Continuous Dopaminergic Stimulation (cds) Is Presently the Drug Delivery System Parkinson's Disease , 2022 .

[60]  Ivan Rektor,et al.  Levodopa‐induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two‐year, prospective follow‐up , 2002, Movement disorders : official journal of the Movement Disorder Society.

[61]  R. J. Harman,et al.  National Institute for clinical excellence preoperative tests: Is the consensus hard to get?: 1AP3-9 , 2007 .

[62]  W. Poewe,et al.  Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. , 1999, Advances in neurology.

[63]  W. Poewe,et al.  Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. , 1993, Advances in neurology.

[64]  A. Hughes,et al.  Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.